Ma Xue-Lei, Liu Lei, Liu Xiao-Xiao, Li Yun, Deng Lei, Xiao Zhi-Lan, Liu Yan-Tong, Shi Hua-Shan, Wei Yu-quan
Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Chengdu, China.
Asian Pac J Cancer Prev. 2012;13(5):2329-34. doi: 10.7314/apjcp.2012.13.5.2329.
Many studies have reported that microRNA-21 (miR-21) mihght predict the survival outcome in non-small cell lung cancers (NSCLCs) but the opposite opinion has also been expressed. The aim of this study was to summarize the evidence for a prognostic role of miR-21.
All the eligible studies was searched by Medline and EMBASE and patients' clinical characteristics and survival outcome were extracted. Then a meta-analysis was performed to clarify the prognostic role of the miR-21 expression in different subgroups.
A total of 8 eligible articles were yielded covering survival outcomes or clinical characteristics. The combined hazard ratio (HR) and 95% confidence interval (95% CI) for overall survival (OS) was 2.19 [0.76, 6.30], while the combined HR (95% CI) of Asian group for OS had a significant result, 5.49 [2.46, 12.27]. The combined HR (95% CI) for recurrence free survival or disease free survival (RFS/DFS) was 2.31 [1.52, 3.49]. Odds ratios (ORs) showed that the miR-21 expression was associated with lymph node status and histological type.
miR-21 expression could predict the prognostic outcome of NSCLC in Asians, despite some deficiencies in the study data.
许多研究报告称，微小RNA-21（miR-21）可能预测非小细胞肺癌（NSCLC）的生存结局，但也有相反的观点。本研究的目的是总结miR-21预后作用的证据。
通过Medline和EMBASE检索所有符合条件的研究，并提取患者的临床特征和生存结局。然后进行荟萃分析，以阐明miR-21表达在不同亚组中的预后作用。
共获得8篇符合条件的文章，涵盖生存结局或临床特征。总生存（OS）的合并风险比（HR）和95%置信区间（95%CI）为2.19[0.76，6.30]，而亚洲组OS的合并HR（95%CI）有显著结果，为5.49[2.46，12.27]。无复发生存或无病生存（RFS/DFS）的合并HR（95%CI）为2.31[1.52，3.49]。优势比（OR）表明，miR-21表达与淋巴结状态和组织学类型相关。
尽管研究数据存在一些不足，但miR-21表达可预测亚洲NSCLC患者的预后结局。
